Clinical Trials in Gütersloh, Germany
2 recruiting
Showing 1–3 of 3 trials
Recruiting
Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca675 enrolled281 locationsNCT06357533
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Phase 2
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest120 enrolled13 locationsNCT06207734